Summary Lumbar bone mineral density (BMD) determination by dual photon absorptiometry was used to study the influence of adjuvant chemotherapy for premenopausal breast cancer on the risk of premature osteoporosis. Six cycles of combination chemotherapy caused ovarian failure in 31 of 44 (71 %) women, amenorrhoea mostly already beginning during treatment. In contrast, only seven of 44 (16%) women, who were pair-matched for age and year of breast cancer surgery and had not been treated with chemotherapy, were post-menopausal at the time of measurement. The mean interval after breast surgery was 3.5 years. The significantly decreased BMD in the treated group (1.17 compared to 1.29 g cm-2) could only be explained by the high incidence of menopause in these women, which on average occurred 10 years prematurely. Extrapolation of these findings suggests that adjuvant chemotherapy may precipitate osteoporotic fractures by some 10 years in a considerable proportion of women cured of premenopausal breast cancer.
Gradual loss of bone matrix and mineral is a consequence of ageing leading to osteoporosis. In general, women start off with less peak adult bone mass than men and consequently develop more symptoms from osteoporosis. As a result a considerable proportion of women suffer from spontaneous fractures in later life (Gordan, 1978; Nordin, 1980; NIH Consensus Statement, 1984) . Various data suggest that in osteoporosis there is a disproportionately greater loss of trabecular bone from the axial skeleton compared to cortical bone from appendicular sites (Riggs et al., 1981) .
The average annual loss of bone mass measured by bone mineral density (BMD) in women before menopause amounts to 1-2%, but may rise to some 6-8% during the first 2-5 years after menopause (Krolner & Pors Nielsen, 1982; Genant et al., 1982) . This dramatic temporary increase in the rate of bone loss around natural menopause or after bilateral ovariectomy has been ascribed to a ceasing protection from bone loss by ovarian hormones (Riggs et al., 1981 (Riggs et al., , 1982 (Riggs et al., , 1986 Genant et al., 1982; Johnston et al., 1985; Richelson et al., 1984) . Oestrogen replacement therapy effectively prevents osteoporosis in post-menopausal women if started within a few years after menopause (Riis, 1987; Lindsay et al., 1976; Christiansen et al., 1980; Recker et al., 1977) .
Adjuvant chemotherapy in premenopausal women treated for breast cancer frequently leads to diminished ovarian function and premature menopause (Henderson, 1987) . Since early menopause is one of the strongest predictors of osteoporosis (Richelson et al., 1984) , we anticipated that the widely used adjuvant chemotherapy regimen of cyclophosphamide, methotrexate and 5-fluorouracil (CMF), might seriously precipitate osteoporosis.
To investigate this possibility we have compared the bone mineral density of the lumbar spine between women who had been treated with adjuvant CMF and women, matched for age and time of premenopausal breast cancer surgery, who received no such treatment.
Materials and methods
Eighty-eight caucasian female patients constituted 44 pairs of cases and controls. Women regarded as cases had received six cycles of CMF adjuvant chemotherapy (Bonadonna et al., 1985) after primary treatment of premenopausal breast cancer with axillary lymph node metastases (pT13, N1-2 MO). Patients were considered post-menopausal when they were amenorrhoeic at the time of measurement, still were during at least one year thereafter, and had serum FSH levels >20 IU ml-' (2nd International Reference Preparation 78/ 549). FSH was determined with a double antibody radioimmuno assay kit from Diagnostic Products Corp. (Los Angeles, CA, USA). Additional information was obtained by questionnaires concerning parity, age at menarche and cigarette smoking habits. Body weight (to the nearest 0.1 kg) and height (to the nearest 0.01 m) were measured and the Quetelet index (kg mg-2) was calculated as a parameter of obesity. The oestrogen receptor (ER) content of the primary tumour was determined as described before (Korsten, 1977) , and was known for 22 matched pairs.
The BMD of the lumbar spine was determined by dual photon absorptiometry as described by Riggs et al. (1982) (De Waard, 1981) . The seven controls became amenorrhoeic at a mean age of 47 years. (Figure 1) . The relationship between BMD and age is demonstrated in Figure 2 . Although age is known to be inversely related to BMD, the large variation in BMD between our patients obscures this correlation. The ER content of the primary tumour which was known for 22 pairs, had no relation with BMD.
Discussion
We have confirmed earlier reports (Bonadonna et al., 1985) that the majority of premenopausal women lost ovarian function as a direct result of six cycles of adjuvant CMF chemotherapy after breast cancer surgery. Our data also show the negative relationship of menopause and BMD as determined over the lumbar spine. It is known that the cessation of ovarian function mainly affects trabecular bone, which constitutes a large part of the vertebral bodies (Riggs et al., 1981 (Riggs et al., , 1982 (Riggs et al., , 1986 Genant et al., 1982; Johnston et al., 1985; Richelson et al., 1984) . In this study BMD differences between the paired cases and controls, matched for chronological age and age at breast surgery, were only explainable by menopausal status. Although we could confirm the positive relationship between obesity and various parameters of bone mass reported by others (Frumar et al., 1980; Daniell, 1976; Kreiger et al., 1982) , and Quetelet index did not significantly contribute to the observed BMD differences between cases and controls. Since oestrogens are generally considered to protect women from physiological bone loss, we have investigated whether factors, other than menopause, which influence the exposure of the skeleton to oestrogens were related to BMD. However, coitrary to what might be expected, parity and (early) age at menarche were not (positively) related to bone mass. Smoking may enhance both the metabolic inactivation of oestrogens (Jensen et al., 1985) and early menopause (Lesko et al., 1985) , and therefore could have a negative influence on BMD. the present study is significantly reduced in osteoporotic women compared to controls (Riggs et al., 1981; Kr0lner & Nielsen, 1982) . Our findings strongly suggest that the accelerated bone loss resulting from premature menopause may eventually contribute to an increased risk of osteoporosis at a relative early age. Seventy-one per cent of the women receiving chemotherapy lost their ovarian protection at a mean age of 41, which in The Netherlands is some 10 years early (De Waard, 1981) . The limitations of the study size and its cross-sectional model do not allow further conclusions. The risk of osteoporotic fractures of the spine, hip and wrist is already considerable in the general female population aged 60-70 (Riggs et al., 1986) . If BMD is a good predictor our findings strongly suggest that a similar risk may apply to breast cancer patients reaching the age of 50-60 who were premenopausal when receiving adjuvant CMF chemotherapy. The high incidence of breast cancer in the Western industrialised world and the widely recommended use of adjuvant chemotherapy in premenopausal breast cancer (Consensus Development Conference Report, 1985; Bonadonna & Valagussa, 1987) constitute an extra challenge to develop effective measures other than exogenous oestrogens to reduce post-menopausal bone loss.
